2 recruiting, 1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow KCNT1-Related Epilepsy: new trials by email Literature Review of KCNT1-Related Epilepsy trials Research Report on KCNT1-Related Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy ABS-1230, Placebo - KCNT1-Related Epilepsy | Phase 2 | Recruiting | Actio Biosciences, Inc. | 61 | 2026-05-18 | 2026-10-15 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years ABS-1230, Placebo, Omeprazole - KCNT1-Related Epilepsy | Phase 1 | Recruiting | Actio Biosciences, Inc. | 92 | 2025-08-28 | 2026-08-07 |
| A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy No Intervention - KCNT1-Related Epilepsy | Completed | Biogen | 35 | 2021-08-17 | 2024-02-28 |
Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (1)
Omeprazole (1) · Voriconazole (1)
Actio Biosciences, Inc. (2) · Biogen (1)
United States (2) · Australia (1)